Voluntarily able to provide consent
Diagnosis of HAE Type I or Type II
Able to use a mobile device for data collection in the study
Participation in any interventional clinical trial at the time of enrollment
Unable to provide consent
Investigator believes patient is not a suitable candidate for the study

Have diagnosis of relapsing multiple sclerosis (RMS)
Have experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to injectable disease-modifying drug treatment
Patients who do not have relapsing multiple sclerosis (RMS)
Patients who are doing well on injectable disease-modifying drugs
Patients who have previously been treated with cladribine in any form
Pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during study

People who have a history of hidradenitis suppurativa
Seen at Penn State Health within the past year
18 years of age or older
Can read/write in English
Have access to the internet
Those who do not meet inclusion criteria

Premenopausal women, 18
•51 years old
Diagnosis of uterine fibroids with heavy menstrual bleeding
Regular menstrual cycles between 24
•38 days in length
Must agree to use at least 2 forms of non-hormonal contraception throughout the study period.
No osteoporosis or other metabolic bone disease
No history of suicide ideation or attempts
Not currently pregnant, breastfeeding or planning to become pregnant until study completion

Histologic or cytologic evidence of advanced or metastatic biliary tract cancer including cholangiocarcinoma (intra-hepatic or extra-hepatic bile ducts), ampullary carcinoma, and gallbladder carcinoma.
Evidence of recurrent, locally advanced, or metastatic disease.
Progressed following or intolerant to one or more line of systemic therapy.
Presence of at least 1 lesion that is measurable or evaluable using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate organ function, as evidenced by the laboratory parameters noted in Study Eligibility.
Ongoing or active infection requiring systemic antibiotics.
History of previous venous thromboembolic events.
Uncontrolled hypertension despite adequate therapy (i.e., systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 90 mm Hg found on 2 separate occasions separated by 1 week).
Diabetes mellitus and occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to the first dose of study drug.
Active second malignancy other than curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or other cancers with no known active disease in the 3 years prior to enrollment.

Be at least 18 years of age
Understand English
Have normal or normal-corrected vision
Can use standard computer monitor, a mouse, and a game controller
Have visual deficiencies where the person is unable to identify the graphical images on a computer monitor from 20” away
Require use of non-standard graphical interfaces or manipulation devices

18 years or older
Karnofsky Performance Status of at least 70
advanced or metastatic renal carcinoma
No prior systemic therapy
No active brain metastases
Use of an investigational agent or an investigational device within 28 days of randomization
autoimmune disease
History of organ or tissue transplant
Prior major surgery or radiotherapy within 14 days
Any tumor invading the major blood vessels

Over age 18
No food allergies
English Speaker
Under age 18
Food allergies
Non-English Speakers

55-75 years old
Non-smoker
BMI between 18.5 – 35 kg/m2
Systolic BP > 160 mmHg or diastolic BP > 100 mmHg
Fasting glucose > 126 mg/dL
Use of cholesterol/lipid-lowering medications
Use of anti-hypertensive medications
Use of glucose lowering medications

Age 18-30
Right-handed
Native speaker of English
At least a high school education
History of neurogenic or psychiatric illness
Pacemaker or other metal implant
Claustrophobia
Medications that affect cognition

Type I or II HAE
Used androgen therapy for prophylaxis of HAE episodes in past 12 months
Greater than or equal 40 kg
Access to appropriate rescue medication for HAE attacks
Pregnant, breastfeeding, or planned pregnancy
Prior enrollment in BCX 7353 study
Known family history of sudden cardiac death

Patients must have histologically proven, T2-T4a N0M0 urothelial carcinoma of the bladder within 70 days prior to randomization.
Patients must undergo radiological staging within 70 days prior to randomization. Imaging of chest, abdomen, and pelvis must be performed using CT or MRI. Patients must not have evidence of T4bN1-3 disease.
Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and kidney function meets criteria specified.
Female patients of childbearing potential must have a serum pregnancy test prior to randomization.
Patients must be ≥ 18 years of age.
Patient must not have received any systemic chemotherapy for their bladder cancer.
Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.
Patients must not have a major surgical procedure within 28 days prior to randomization.
Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation.
Patients must have adequate bone marrow function as evidenced by all of the following: ANC ≥ 1,500/microliter (mcL); platelets ≥ 100,000/mcL; Hemoglobin ≥ 9 g/dL. These results must be obtained within 28 days prior to randomization.

Age 18-75
Forced vital capacity ≥ 70% predicted
ALS symptom onset within 3 years
Undergoing treatment for cancer
Pregnancy or lactation
Hereditary fructose intolerance
Unable to take medications orally
History of hypersensitivity to edaravone

Between age of 4.5-6.0 years-old
No food allergies
Taking medication that can affect taste or appetite

At least 18 years of age.
Currently living in Centre County, PA.
Expect to continue living in Centre County, PA (through at least Sept 2020)
Capable of providing your own informed consent.
No additional exclusion criteria beyond those required for inclusion.

Confirmed diagnosis of CML ≥ 18 months from diagnosis
Current concomitant treatment with TKI therapy (Imatinib, Dasatinib, Nilotinib or Bosutinib; excluding Ponatinib)
BCR-ABL PCR at stable molecular disease (e.g. MMR stable but not CMR) or b. Hematologic remission (HR) but no MMR
Stable molecular response defined as 2 sequential BCR-ABL levels done in the same lab with less than ½ log reduction of BCR-ABL (BA)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score more than or equal to 3
Current malignancy requiring active treatment
Active infection requiring antibiotic treatment
Known HIV, Hepatitis B, or Hepatitis C infection
Known symptomatic congestive heart failure (CHF), unstable angina or cardiac arrhythmia
Current concomitant use of NSAIDs (including Aspirin) or COX-1; a washout period of 4 weeks prior to enrollment is permitted

A confirmed diagnosis of neuroblastoma.
Must be 21 years of age or younger when diagnosed.
No prior systemic therapy with some exceptions.
Tumor samples will be obtained only in a non-significant risk manner and not solely for the purpose of the study.
Receiving another study drug while on this study.
Female patients who are lactating are not eligible unless they agree not toe breast feed.

< 6 years old at the time of screening
previously untreated with < 3 EDs to ADVATE, BAX 855 or FFP any time prior to screening
severe hemophilia A (FVIII < 1%)
History or current FVIII inhibitory antibodies (≥ 0.6 BU
Diagnosis of an inherited or acquired hemostatic defect other than hemophilia A
Previously treated with cryo, PRBC, platelets or any type of FVIII concentrate other than ADVATE, BAX 855v or FFP
weight is < 5 kg
Platelet count < 100,000/mL; severe chronic hepatic dysfunction or severe renal impairment

Individuals who understand English
Individuals who hold a dependent (F-2/J-2) visa status
Non-English speakers
Age under 18
Non-dependents (F-2/J-2) visa status
Anyone who cannot consent to participate in this study

Any adult over the age of 18 years
Opens to males and females
Anyone under the age of 18 years old

A physician-documented parkinsonian symptom onset between the ages of 40-59 will
Patients should not have reached their 65th birthday.
Patients that have tremor, rigidity, and bradykinesia unilaterally
Dementia
Autonomic dysfunction
Parkinson-plus syndrome
Postural instability
History of exposure to substances that cause parkinsonism

Any age
Ability of patient, child and/or parent to understand or complete the consent process
Unable to understand or complete the consent process
Opted out of research studies

Penn State Affiliation
Under age 18

Have Fabry Disease
Be willing an able to provide written informed consent
None

At least 18 years old
Younger than 18 years old

A diagnosis of severe aplastic anemia.
Less than 75 years of age at time of enrollment.
Failed at least one trial of immunosuppressive therapy.
Inherited bone marrow failure syndromes.
Diagnosis of myelodysplastic syndrome.
Prior allogeneic stem cell transplant or solid organ transplant.

6 years old and greater
Must have Cystic Fibrosis (CF)
Positive culture for MRSA at screening
FEV1 between 30-90%
Commit to 14 visits over 12 months
You may not have allergies to vancomycin
Abnormal liver or kidney function
Inability to tolerate inhaled products

parent
guardian
child in elementary / middle school
live in or around a low income community
no children in school
not a parent or guardian

Male
Competitive athlete
Penn State student
18+ years
Female
Non-athlete
Non-student
Under 18 years

Participants must be adult male and female volunteers over the age of 18 at the time of enrollment.
Participants must not have an immune disease or significant medical illness.
Participants must currently be a non-smoker.
Participants cannot be pregnant or breast feeding.
Individuals with an immune disease or significant medical illness will be excluded from this study.
Individuals who currently smoke will be excluded from this study.
Individuals who are currently pregnant will be excluded from this study.